2018
HOUT-27. THE CHALLENGE OF HEALTH UTILITY VALUES FOR GLIOBLASTOMA PATIENTS WITH LONG-TERM SURVIVAL
Blondin N, Proescholdt C, Kelly J. HOUT-27. THE CHALLENGE OF HEALTH UTILITY VALUES FOR GLIOBLASTOMA PATIENTS WITH LONG-TERM SURVIVAL. Neuro-Oncology 2018, 20: vi119-vi119. PMCID: PMC6217248, DOI: 10.1093/neuonc/noy148.495.Peer-Reviewed Original ResearchQuality-adjusted life yearsHealth utility valuesLong-term survivorsLong-term survivalHealth utilityCondition-specific questionnaireEF-14 trialQuality of lifeHealth economic evaluationsGeneral population sampleStable diseaseAdverse eventsPreference-based measuresMultiple myelomaGBM patientsHealth state scenariosGlioblastoma patientsPatientsGBM treatmentSurvival rateLife yearsNew treatmentsUtility valuesDiagnosisHealth Panel
2017
PALL-07. COMPLEMENTARY CANNABIS THERAPY FOR MALIGNANT GLIOMA: INITIAL EXPERIENCE
Blondin N. PALL-07. COMPLEMENTARY CANNABIS THERAPY FOR MALIGNANT GLIOMA: INITIAL EXPERIENCE. Neuro-Oncology 2017, 19: vi169-vi169. PMCID: PMC5692009, DOI: 10.1093/neuonc/nox168.688.Peer-Reviewed Original ResearchMalignant glioma patientsCannabis treatmentGlioma patientsCannabis therapyInitial experienceTherapeutic useBeneficial palliative effectBrain tumor symptomsCertain medical conditionsLow usePalliative useStandard therapyTumor symptomsOral sprayTherapeutic roleMalignant gliomasPalliative effectMild fatigueAnaplastic astrocytomaMedical conditionsAstrocytoma casesGlioblastoma patientsPatientsSide effectsAnimal models